INDIGO: Obexelimab vs Placebo in Active IgG4-Related Disease (2026) — Trial Summary

INDIGO: Obexelimab vs Placebo in Active IgG4-Related Disease (2026): Phase 3, double-blind, randomized, placebo-controlled trial in adults with active IgG4-related disease. Weekly subcutaneous obexelimab 250 mg versus placebo for 52 weeks; standardized glucocorticoid taper to discontinuation by week

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.